Authors
Latest:
PARP Inhibitor Costs Give Patients With Ovarian Cancer Financial ToxicityRoss F. Harrison, MD, discusses the out-of-pocket costs for patients with ovarian cancer receiving PARP inhibitor treatment.
Latest:
No Increase of Grade 3/4 AEs Seen With Polatuzumab Vedotin Plus R-mini-CHOP in DLBCLThe use of polatuzumab vedotin in place of vincristine in R-mini-CHOP may lead to an increase in gastrointestinal adverse events in frail patients with diffuse large B-cell lymphoma.
Latest:
Rashdan Explores the Safety/Efficacy of Osimertinib and SABR in EGFR+ NSCLCSawsan Rashdan, MD, discusses the background, findings, and next steps of a phase 2 study evaluating treatment with osimertinib and consolidative SABR for the treatment of EGFR-mutated NSCLC.
Latest:
Advances in the Treatment of SarcomasLisa B. Ercolano, MD, discusses some of the advances that have been seen in the treatment of sarcomas.
Latest:
Soiffer Discusses Relapse After TransplantRobert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.
Latest:
Sacituzumab Govitecan Shows Consistent Efficacy in Real-World mTNBCIn metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.
Latest:
Academic Perspectives for LR-MDS Treatment in the CommunityPanelists discuss key learnings from recent studies on lower-risk myelodysplastic syndrome (LR-MDS) treatment, identify remaining knowledge gaps, and offer final takeaways, including their thoughts on the role of luspatercept in the evolving LR-MDS treatment landscape, clinical pearls for community oncologists, and major unanswered questions that could improve outcomes for LR-MDS and anemia management in the future.
Latest:
Tisotumab Vedotin Improves Treatment Options in Cervical CancerSusan C. Modesitt, MD, discusses the introduction of antibody drug conjugate tisotumab vedotin to treatment for patients with metastatic cervical cancer.
Latest:
Emerging TRK Inhibitors Are Explored Across Cancer SettingsTargeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to target the BCR-ABL fusion in chronic myelogenous leukemia.
Latest:
Behind the DeFi Trial: Nirogacestat for Patients With Desmoid TumorsBernd Kasper, MD, PhD, provides an overview of the phase 3 DeFi trial of nirogacestat for the treatment of patients with progressing desmoid tumors.
Latest:
ASCO 2025: Highlights From TiNivo-2 TrialPanelists discuss how recent updates in progression free survival data complement secondary endpoints of overall survival, overall response rates, and duration of response to provide a comprehensive picture of treatment efficacy.
Latest:
Key Updates in Lower-Risk MDSIn the fifth article of this series, Yazan Madanat, MD, reviews recent updates presented at the 2023 ASH Annual Meeting and discusses the evolving treatment landscape.
Latest:
Upcoming Insights – Strategies for Management of Dermatological Reactions from Combination Amivantamab/ Lazertinib for EGFR-mutated NSCLCA panelist discusses adverse events with amivantamab and provides new recommendations for managing these skin-related events.
Latest:
JAK Inhibitors Emerge as a Cornerstone Therapy for MyelofibrosisWith multiple JAK inhibitors now available to choose from, patient- and disease-specific factors are vital in determining the most appropriate therapy for patients with myelofibrosis.
Latest:
Role of Tumor-Infiltrating Lymphocytes in Solid Tumors: Advancements in Therapeutic StrategyIn the first interview of this series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale of tumor-infiltrating lymphocytes and considers their potential use in the management of solid tumors.
Latest:
Vepdegestrant Improves PFS in ESR1-Mutated Breast CancerVepdegestrant extended PFS vs fulvestrant in patients with ESR1m+, ER+/HER2– breast cancer who progressed on CDK 4/6 inhibitors and endocrine therapy.
Latest:
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCCIn this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Latest:
About NRG GY018: Pembrolizumab Plus Chemotherapy in Endometrial CancerJohn Nakayama, MD, discusses the significance of the NRG GY018 study in endometrial cancer.
Latest:
Integrating Rheumatology Into Cancer Immunotherapy CareAlexa Simon Meara, MD, discusses the importance of including a rheumatology approach to immunotherapy treatment for cancer.
Latest:
Optimizing Treatment in Myeloma With Biweekly Dosing of TalquetamabCesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.
Latest:
Updates in the Management of Diffuse Large B-Cell LymphomaYazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.
Latest:
Ovarian Function Suppression Improves Survival in Premenopausal Women with HR+, HER2+ Breast CancerSun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress.
Latest:
In Advanced Prostate Cancer, a String of Modest Gains Are Changing Patient CareRobert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.
Latest:
Can New Protocols Reduce Costs of Multiple Myeloma Treatment?Daniel Cancilla, MD, discusses a study performed at the Cleveland Clinic where a new protocol for plerixafor usage for stem cell transplantation was implemented with the goal of cost savings.
Latest:
Brain Benefits: Targeted Therapy Offers New Weapon Against HER2+ Breast Cancer with LMMina Lobbous, MD, MPH, discusses findings and implications fro a study investigating a new regimen for the treatment of brain metastases in patients with HER2-positive breast cancer.
Latest:
Convenient Saliva Test Could Predict Head and Neck Cancer RecurrenceElizabeth Franzmann, MD, discusses findings of a study exploring a novel method of testing recurrence of head and neck cancer.
Latest:
Promising New Therapy for Hematologic Malignancies in Young PatientsAlice Bertaina, MD, discusses combining of T-allo10, a donor-derived cell product, with haploidentical stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.
Latest:
Unmet Needs in R/R MM and Clinical Practice PearlsClosing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.
Latest:
Looking Ahead for Melanoma TreatmentJose Lutzky, MD, discusses clinical trials investigating novel therapies for melanoma.
